Unclassifiable myelodysplastic disease: a clinical case report
DOI:
https://doi.org/10.55204/trc.v6i2.e743Keywords:
Myelodysplastic syndrome, Nursing care process, Severe anemia, Azacitidine, HyperleukocytosisAbstract
Myelodysplastic syndromes are clonal hematological neoplasms characterized by ineffective hematopoiesis and cytopenias, unclassifiable variants represent a diagnostic challenge due to their atypical manifestations and inconsistencies in current classification systems. Objective: To present the clinical case of a patient with unclassified myelodysplastic/myeloproliferative neoplasm and to evaluate the impact of an individualized care plan based on the Nursing Care Process. Methodology: Descriptive, qualitative and cross-sectional study of clinical case report in a hospital in Manabí. The clinical history of a 58-year-old man with severe anemia and hyperleukocytosis was analyzed, structuring nursing interventions using the NANDA-I, NOC and CIN taxonomies. Results: Grade IV severe anemia (Hb: 6.0 g/dL) and hyperleukocytosis (81,900 /μL) were identified. The application of ECP by guided transfusion support restored hemodynamic stability and tissue perfusion (HR: 78 bpm, SpO₂: 98%). Prophylaxis with allopurinol and hyperhydration prevented tumor lysis syndrome during azacitidine administration, achieving a favorable clinical outcome without infectious events or serious toxicities. Conclusion: Structured ECP allowed for effective comprehensive management, stabilizing complex cytopenias and preventing metabolic and infectious complications, which facilitated safe hospital discharge to outpatient follow-up.Downloads
References
1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391–405. doi:10.1182/blood-2016-03-643544
2. Ogawa S. Genetics of MDS. Blood. 2019 Mar 7;133(10):1049–59. doi:10.1182/blood-2018-10-844621
3. Cazzola M. Myelodysplastic Syndromes. New England Journal of Medicine. 2020 Oct;383(14):1358–74. doi:10.1056/NEJMra1904794
4. Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019 Mar;34:1–15. doi:10.1016/j.blre.2018.09.001
5. Cogle CR. Incidence and Burden of the Myelodysplastic Syndromes. Curr Hematol Malig Rep. 2015 Sep 2;10(3):272–81. doi:10.1007/s11899-015-0269-y
6. Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J. 2018 May 24;8(5):47. doi:10.1038/s41408-018-0085-4
7. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 2007 Jun;31(6):727–36. doi:10.1016/j.leukres.2006.11.009
8. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul 22;36(7):1703–19. doi:10.1038/s41375-022-01613-1
9. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200–28. doi:10.1182/blood.2022015850
10. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood. 2012 Sep 20;120(12):2454–65. doi:10.1182/blood-2012-03-420489
11. Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evidence. 2022 Jun 28;1(7). doi:10.1056/EVIDoa2200008
12. INEC. VIII Censo de Población y VII de Vivienda 2022. Quito; 2022 Dec.
13. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul 22;36(7):1703–19. doi:10.1038/s41375-022-01613-1
14. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200–28. doi:10.1182/blood.2022015850
15. Credland N, Gerber K. Humanizing critical care. Nurs Crit Care. 2021 Jul 29;26(4):222–3. doi:10.1111/nicc.12673
16. Rojas Corona L, Vidal Andrade E, Cerón Díaz UW. Índice de PaO<sub>2</sub>/FAO<sub>2</sub>: ¿un mejor indicador de oxigenación para valorar la hipoxemia? Resultados de un análisis de concordancia con el índice de PaO<sub>2</sub>/FiO<sub>2</sub> Medicina Crítica. 2023;37(1):21–5. doi:10.35366/109958
17. Escalante López JI, Medina Valderrama CJ, Vásquez Muñoz A. La deserción universitaria: un problema no resuelto en el Perú. Hacedor - AIAPÆC. 2023 Jun 30;7(1):60–72. doi:10.26495/rch.v7i1.2421
18. Demakos EP, Linebaugh JA. Advances in Myelodysplastic Syndrome: Nursing Implications of Azacitidine. Clin J Oncol Nurs. 2005 Aug 1;9(4):417–23. doi:10.1188/05.CJON.417-423
19. Instituto Nacional de Estadisticas y Censos. INEC revela principales causas de hospitalización en ecuador: cálculos biliares, neumonía y apendicitis lideran el ranking. Quito; 2025 Jul.
20. López Pino María José. Salud Pública En Ecuador Como Factor De Desarrollo Social: una revisión bibliográfica. Vol. 6. 2023 Jul;6(12):1–31.
21. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200–28. doi:10.1182/blood.2022015850
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Melissa Nicole Alcázar Zambrano, Bryan Steeven Macías Macías, Viviana Gricelda Vélez Navarrete, Katherine Rocio Lascano Molina
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain the moral and patrimonial rights of their works. They only give to the magazine Tesla Revista Científica the right to the first publication of this. Since Tesla Revista Científica is an open access publication, readers can fully or partially reproduce its content as long as they properly credit the corresponding authors and the journal itself. Tesla Revista Científica undertakes not to make commercial use of the texts it receives and/or publishes.
Our journal is governed by the international policies SHERPA/RoMEO: Green journal: They allow the self-archiving of both the pre-print (draft of a paper) and the post-print (the version corrected and reviewed by peers) and even the final version ( layout as it will be published in the journal).
See also "Copyright and licences".
